AI Article Synopsis
- The gut microbiota may influence how patients with cancer respond to immune checkpoint inhibitors (ICIs), but using it as a reliable biomarker is complicated.
- A recent study published in Cell by Derosa et al. introduces a two-tier model that analyzes gut microbiota composition to distinguish between patients who respond positively and those who do not to ICIs.
- This research provides promising insights that could be utilized in clinical settings to improve cancer treatment outcomes. *
Article Abstract
The gut microbiota has emerged as a potential determinant of immune checkpoint inhibitor (ICI) response, yet using it as a biomarker remains challenging. A recent study in Cell by Derosa et al. describes a two-tier model based on gut microbiota composition to discriminate responder from non-responder patients with cancer, offering new ideas that could be leveraged in the clinic.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.trecan.2024.07.007 | DOI Listing |
Publication Analysis
Top Keywords
gut microbiota
8
enhancing predictive
4
predictive microbiota
4
microbiota cancer
4
cancer immunotherapy
4
immunotherapy gut
4
microbiota emerged
4
emerged potential
4
potential determinant
4
determinant immune
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!